Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-12-05
Target enrollment:
Participant gender:
Summary
Researchers plan to enroll a total of 100 patients with relapsed, refractory acute myeloid
leukemia (AML) to receive a single dose of autologous CAR T cells.The safety of CAR T therapy
was evaluated by observing adverse events after cell therapy;The efficacy of CAR-T therapy
was evaluated against the outcome of patients' own past standard treatment regimens or
historical data.Blood and bone marrow were collected before and 12 months after infusion to
detect the number and activity of CAR T cells, and to evaluate the pharmacokinetics (PK) of
CAR T cells.
Phase:
Early Phase 1
Details
Lead Sponsor:
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China